使用左心室辅助装置患者的COVID-19

Q4 Medicine

Clinical and Experimental Surgery Pub Date : 2022-01-01 DOI:10.33029/2308-1198-2022-10-2-7-12

M. Bekbossynova, Ai.T. Tauyekelova , N. Khissamutdinov

{"title":"使用左心室辅助装置患者的COVID-19","authors":"M. Bekbossynova, Ai.T. Tauyekelova , N. Khissamutdinov","doi":"10.33029/2308-1198-2022-10-2-7-12","DOIUrl":null,"url":null,"abstract":"Background. Coronavirus infection (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Patients with cardiovascular disease especially patients with advanced heart failure are at particularly high risk of morbidity and mortality. Patients with left ventricular assist device (LVAD) represent a unique population at risk because of comorbidities and functionally compromised immunity. Аim of this article was to analyze clinical cases of COVID-19 among LVAD patients of the Republic of Kazakhstan. Material and methods. Characteristics of LVAD patients of the Republic of Kazakhstan who developed COVID-19 between March 2020 and August 2021, initial manifestations of the disease, comorbidities, complications and clinical outcomes were collected and analyzed. Results. A total of 177 patients with LVAD who were supported and registered by the NAO “National Scientific Cardiac Surgery Center” were interviewed. 41 (23.2%) patients had classic COVID-19 symptoms. The mean age of the patients was 55 years (interquartile range, 17-75), and 9 (21.9%) patients were female. The majority of patients (n=36, 87.8%) were implanted with LVAD HeartMate 3. The largest number, 19 (46%) patients, were patients with dilated cardiomyopathy (DCM). The time of LVAD support ranged from 1 month to 83 months before the onset of symptoms and diagnosis of COVID-19. 13 (31.7%) patients required hospitalization due to decreased oxygen saturation (less than 94%) and oxygen deprivation. 3 patients (1.7% among 177 supported patients and 7.3% among patients with COVID-19) required care and treatment in an intensive care unit. Conclusion. We presented an analysis of clinical cases in LVAD patients with COVID-19 in Kazakhstan. To note, there are no guidelines for management and treatment, no data related to the clinical course of COVID-19 in patients on LVAD support to date. Close monitoring of clinical status, anticoagulation and frequent collection of device parameters and DL exit site images, precautionary measures consideration, early diagnosis, timely initiated treatment, supportive psychological care, multidisciplinary approach and rigorous follow-up are crucial in the management of LVAD patients with COVID-19.","PeriodicalId":53448,"journal":{"name":"Clinical and Experimental Surgery","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"COVID-19 in patients with left ventricular assist device\",\"authors\":\"M. Bekbossynova, Ai.T. Tauyekelova , N. Khissamutdinov\",\"doi\":\"10.33029/2308-1198-2022-10-2-7-12\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background. Coronavirus infection (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Patients with cardiovascular disease especially patients with advanced heart failure are at particularly high risk of morbidity and mortality. Patients with left ventricular assist device (LVAD) represent a unique population at risk because of comorbidities and functionally compromised immunity. Аim of this article was to analyze clinical cases of COVID-19 among LVAD patients of the Republic of Kazakhstan. Material and methods. Characteristics of LVAD patients of the Republic of Kazakhstan who developed COVID-19 between March 2020 and August 2021, initial manifestations of the disease, comorbidities, complications and clinical outcomes were collected and analyzed. Results. A total of 177 patients with LVAD who were supported and registered by the NAO “National Scientific Cardiac Surgery Center” were interviewed. 41 (23.2%) patients had classic COVID-19 symptoms. The mean age of the patients was 55 years (interquartile range, 17-75), and 9 (21.9%) patients were female. The majority of patients (n=36, 87.8%) were implanted with LVAD HeartMate 3. The largest number, 19 (46%) patients, were patients with dilated cardiomyopathy (DCM). The time of LVAD support ranged from 1 month to 83 months before the onset of symptoms and diagnosis of COVID-19. 13 (31.7%) patients required hospitalization due to decreased oxygen saturation (less than 94%) and oxygen deprivation. 3 patients (1.7% among 177 supported patients and 7.3% among patients with COVID-19) required care and treatment in an intensive care unit. Conclusion. We presented an analysis of clinical cases in LVAD patients with COVID-19 in Kazakhstan. To note, there are no guidelines for management and treatment, no data related to the clinical course of COVID-19 in patients on LVAD support to date. Close monitoring of clinical status, anticoagulation and frequent collection of device parameters and DL exit site images, precautionary measures consideration, early diagnosis, timely initiated treatment, supportive psychological care, multidisciplinary approach and rigorous follow-up are crucial in the management of LVAD patients with COVID-19.\",\"PeriodicalId\":53448,\"journal\":{\"name\":\"Clinical and Experimental Surgery\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical and Experimental Surgery\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.33029/2308-1198-2022-10-2-7-12\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33029/2308-1198-2022-10-2-7-12","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

背景。冠状病毒感染(COVID-19)是一种由严重急性呼吸综合征冠状病毒2 (SARS-CoV-2)引起的传染病。心血管疾病患者特别是晚期心力衰竭患者的发病率和死亡率特别高。由于合并症和免疫功能受损，使用左心室辅助装置(LVAD)的患者是一个独特的高危人群。Аim的目的是分析哈萨克斯坦共和国LVAD患者中COVID-19的临床病例。材料和方法。收集并分析2020年3月至2021年8月哈萨克斯坦共和国发生COVID-19的LVAD患者的特征、疾病的初始表现、合并症、并发症和临床结局。结果。对NAO“国家科学心脏外科中心”支持登记的177例LVAD患者进行访谈。41例(23.2%)有典型症状。患者平均年龄55岁(四分位数范围17-75岁)，女性9例(21.9%)。大多数患者(n=36, 87.8%)植入了LVAD HeartMate 3。扩张型心肌病(DCM)患者最多，为19例(46%)。LVAD支持时间为出现症状和诊断COVID-19前1 ~ 83个月。13例(31.7%)患者因血氧饱和度降低(小于94%)和缺氧而住院。3名患者(在177名支持患者中占1.7%，在COVID-19患者中占7.3%)需要在重症监护病房进行护理和治疗。结论。我们提出了一项对哈萨克斯坦COVID-19 LVAD患者临床病例的分析。值得注意的是，目前还没有关于管理和治疗的指南，也没有与LVAD支持患者的COVID-19临床病程相关的数据。密切监测临床状态、抗凝及频繁采集器械参数和DL出口部位图像、考虑预防措施、早期诊断、及时开始治疗、支持性心理护理、多学科结合、严格随访是LVAD合并COVID-19患者管理的关键。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

COVID-19 in patients with left ventricular assist device

Background. Coronavirus infection (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Patients with cardiovascular disease especially patients with advanced heart failure are at particularly high risk of morbidity and mortality. Patients with left ventricular assist device (LVAD) represent a unique population at risk because of comorbidities and functionally compromised immunity. Аim of this article was to analyze clinical cases of COVID-19 among LVAD patients of the Republic of Kazakhstan. Material and methods. Characteristics of LVAD patients of the Republic of Kazakhstan who developed COVID-19 between March 2020 and August 2021, initial manifestations of the disease, comorbidities, complications and clinical outcomes were collected and analyzed. Results. A total of 177 patients with LVAD who were supported and registered by the NAO “National Scientific Cardiac Surgery Center” were interviewed. 41 (23.2%) patients had classic COVID-19 symptoms. The mean age of the patients was 55 years (interquartile range, 17-75), and 9 (21.9%) patients were female. The majority of patients (n=36, 87.8%) were implanted with LVAD HeartMate 3. The largest number, 19 (46%) patients, were patients with dilated cardiomyopathy (DCM). The time of LVAD support ranged from 1 month to 83 months before the onset of symptoms and diagnosis of COVID-19. 13 (31.7%) patients required hospitalization due to decreased oxygen saturation (less than 94%) and oxygen deprivation. 3 patients (1.7% among 177 supported patients and 7.3% among patients with COVID-19) required care and treatment in an intensive care unit. Conclusion. We presented an analysis of clinical cases in LVAD patients with COVID-19 in Kazakhstan. To note, there are no guidelines for management and treatment, no data related to the clinical course of COVID-19 in patients on LVAD support to date. Close monitoring of clinical status, anticoagulation and frequent collection of device parameters and DL exit site images, precautionary measures consideration, early diagnosis, timely initiated treatment, supportive psychological care, multidisciplinary approach and rigorous follow-up are crucial in the management of LVAD patients with COVID-19.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical and Experimental Surgery Medicine-Surgery

CiteScore

0.40

自引率

0.00%

发文量

期刊介绍： Journal “Clinical and Experimental Surgery. Petrovsky journal” – a broad-based journal on surgery established to merge all the surgical specialties into the integrated intellectual space provided with up to date systems of communication and information. Following this aim the on-line support of the journal involves extended version and multimedia materials. As soon as the modern surgery has exceeded the scopes of the application-oriented science, the editorial board will encourage the researches of academic importance and facilitate creation of the fresh lines of research as well as the translation of the research results into the practical surgery. Broad-based profile of the journal and multidisciplinary approach to the arrangement of the research materials are to create a start point for the discussions activating the development of the innovative, joint cross-sectoral and international projects. Thematic scope of the journal: Cardiac and vascular surgery Thoracic surgery Abdominal surgery Transplantation and artificial organs Endoscopic surgery Reconstructive and microvascular surgery Physiology, physiopathology, diagnostics Fundamental research and interdisciplinary technologies Education Bioethics History of surgery.